Hurley Patrick, Alnajjar Fawzeyah, Wijesinghe Susanne, Nanus Dominika E, Davis Edward T, Jones Simon W
Institute of Inflammation and Ageing, MRC-ARUK Centre for Musculoskeletal Ageing Research, University of Birmingham, Birmingham, B15 2WB, UK.
The Royal Orthopaedic Hospital NHS Foundation Trust, Bristol Road South, Northfield, Birmingham, B31 2AP, UK.
J Orthop. 2019 Jun 10;16(5):434-439. doi: 10.1016/j.jor.2019.06.014. eCollection 2019 Sep-Oct.
The purpose was to evaluate the effect of Local infiltration analgesia (LIA) reagents in monotherapy and in combinations at clinical doses, on the viability and function of osteoblasts isolated from hip OA patients undergoing orthopaedic surgery. Human hip OA osteoblasts were exposed to LIA reagents including Bupivacaine, Lidocaine, Ropivacaine, Ketorolac and combinations with Adrenaline for 30 min. Osteoblast cellular viability and function was determined at 24 h and 7 days post-exposure. In conclusion, our data shows that LIA reagents, most notably Bupivacaine and its use in combination, are detrimental to human hip OA osteoblasts at concentrations advocated for clinical use.
目的是评估局部浸润镇痛(LIA)试剂在临床剂量下单用及联合使用时,对接受骨科手术的髋骨关节炎(OA)患者分离出的成骨细胞的活力和功能的影响。将人髋OA成骨细胞暴露于包括布比卡因、利多卡因、罗哌卡因、酮咯酸以及与肾上腺素联合使用的LIA试剂中30分钟。在暴露后24小时和7天测定成骨细胞的细胞活力和功能。总之,我们的数据表明,LIA试剂,最显著的是布比卡因及其联合使用,在临床推荐浓度下对人髋OA成骨细胞有害。